Throne Biotechnologies

03/23/2022

We are honored to announce that Throne Biotechnologies is one of the awardees of "5 Best Biotech Companies to Watch" by the Silicon Review!

To support Throne on our journey, check out our equity Crowdfunding campaign here: https://www.startengine.com/throne-biotechnologies

03/19/2022

We are very excited that our equity crowdfunding campaign is live on StartEngine! The Press Release of this campaign has been widely published in major social media such as Time, Entrepreneur, US Weekly, Newsday, Washington Times, The Hill, Chicago Tribune, Daily Press, Reader’s Digest, Life and Style Magazine, Wall Street Business News, NBC-2, ABC-7, and etc.

Throne Biotechnologies (Throne), one of the global-leading biotech companies aiming to achieve the FDA approval on the Stem Cell Educator therapy and find a cure for type 1 diabetes, alopecia areata and other autoimmune diseases. Those interested in facilitating the clinical transition of Stem Cell Educator therapy can visit the Throne campaign page to learn more and invest on StartEngine: https://www.startengine.com/throne-Throne Biotechnologies

03/19/2022

Throne Biotechnologies, one of the global-leading biotech companies aiming to find a cure for type 1 diabetes, announced the launch of their Regulation Crowdfunding raise to support the United States FDA-approved phase 2 clinical trials of Stem Cell Educator therapy to treat type 1 diabetes, alopecia areata and other autoimmune diseases.

"We are so excited to launch this equity crowdfunding through the platform at StartEngine," said Founder and CEO, Dr. Yong Zhao. "Throne is aiming to achieve the Practical Cure for type 1 diabetes, alopecia areata, and other autoimmune diseases through its patented technology, Stem Cell Educator therapy — a one-time, dialysis-like treatment that fundamentally 're-educates' the defective patient's immune system back to health."

Equity crowdfunding gives Throne an opportunity to raise capital from the public. Investors hold partial ownership in the company and have the opportunity to profit if the company does well. Those interested in facilitating the clinical transition of Stem Cell Educator therapy can join the company's equity crowdfunding campaign on StartEngine: https://www.startengine.com/throne-biotechnologies

12/04/2021

Throne Welcomes Renowned Endocrinologist and Scientist, Dr. Theodore Mazzone, as Chief Medical Officer! 🥳🤩

See the full press release here: https://thronebio.com/latestupdates/2021/12/3/throne-welcomes-renowned-endocrinologist-and-scientist-dr-theodore-mazzone-as-chief-medical-officer

11/17/2021

We are working on something big! Stay tuned!

07/09/2021

Dr. Yong Zhao talks about fundraising, the sustainability of Educator Therapy, and the future of Throne Biotechnologies with Life Science Nation. Read the exclusive interview here: https://blog.lifesciencenation.com/category/innovators-pitch-challenge/

06/16/2021

WE WON!! Throne was awarded 1st place for having the most innovative technology among 49 other companies competing in the 2021 RESI Innovator’s Pitch Challenge (IPC) hosted by Life Science Nation.

04/22/2021

EXCITING ANNOUNCEMENT! Stem Cell Educator Therapy is FDA approved to begin phase II clinical trials treating COVID-19!

Similar to Throne's diabetes research, Stem Cell Educator Therapy will aim to reset and strengthen compromised immune systems while reducing mortality rates among existing COVID-19 patients.

04/20/2021

Which biopharma startups will compete at INVEST Pitch Perfect?

Read the exclusive details here —
https://medcitynews.com/2021/04/which-biopharma-startups-will-compete-at-invest-pitch-perfect/?rf=1

03/01/2021

That's a wrap! We just finished shooting an interview with a young Stem Cell Educator Therapy recipient. Stay tuned for what his life with type 1 diabetes looks like now, two years after treatment!

02/18/2021

We are excited to announce that we have changed our name! Formerly Tianhe Stem Cell Biotechnologies, we are now Throne Biotechnologies.

01/10/2021

For the third time, Stem Cell Educator Therapy has been named one of the world's top 7 active practical cure projects for type 1 diabetes in the 9th annual edition of 'The State of the Cure for Type 1 Diabetes 2020.'

Among the 592 active T1D human trials conducted in 2020, only 2% are pursing a practical cure for the disease. Additionally, Stem Cell Educator Therapy is the only technology to reach Phase II/III.

Click the link to read the full report released by the Juvenile Diabetes Cure Alliance: http://thejdca.org/state-of-the-cure-2020-1

12/18/2020

It's here! Listen to Dr. Zhao share his story of developing Stem Cell Educator Therapy, answer commonly asked questions, and his ambitions for the future of precision medicine.

Welcome to TheSugarScience Podcast where our mission is to highlight and connect researchers in the type 1 diabetes space. The(sugar)science is an interactive digital platform founded to curate the scientific conversation among type 1 diabetes (T1D) rese...

12/07/2020

We have joined the MATTER startup community!

The newest MATTER startups are improving patient management, providing access to underserved communities, creating safe treatment for tumor removals and more. Take a minute to meet them and see the heroic change in healthcare happening today.

12/01/2020

10/29/2020

We know the COVID-19 pandemic has impacted individuals with autoimmune and chronic conditions the most.
Our team wants to know how YOU are doing. Comment below!